Streamlining Biologics Prior Auth in Illinois

The Unique Landscape of Biologics Prior Auth in Illinois

Providers operating in Illinois face a dynamic environment shaped by diverse commercial payer footprints and state-specific Medicaid managed care organizations. Each payer may impose distinct criteria for biologics, including indication-specific requirements, step therapy protocols, and biosimilar substitution mandates. Effectively managing these variations is critical to ensuring timely access to essential therapies for patients across rheumatology, gastroenterology, dermatology, and other specialties.

Core Challenges in Biologics Prior Authorization Workflows

• Navigating indication-specific PA criteria for a wide range of biologics.
• Adhering to complex step therapy requirements and documenting prior-line therapy history.
• Complying with payer-specific biosimilar substitution policies.
• Gathering and documenting essential screening requirements (e.g., TB, hepatitis, immunizations).
• Managing periodic re-authorization cycles for chronic biologic treatments.
• Differentiating between medical and pharmacy benefit routing for the same agents.

Klivira's Automated Approach to Biologics PA in Illinois

Klivira's platform is engineered to address the specific demands of biologics prior authorization, offering a streamlined workflow that integrates directly with existing EMR systems. Our solution automates critical steps, from initial submission to re-authorization, significantly reducing manual effort and accelerating approval times. This automation is particularly impactful for high-volume specialty pharmacy PA, as recognized by industry benchmarks like the CAQH Index.

Klivira's Biologics Prior Authorization Workflow Automation

• **Indication Classification:** Automatically identifies the specialty and disease state from EMR diagnoses, ensuring accurate PA criteria application.
• **Step Therapy Automation:** Pulls prior-line therapy history (e.g., csDMARDs, 5-ASA, topical/phototherapy) to fulfill payer step therapy requirements.
• **Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates, guiding appropriate product selection.
• **Screening Documentation:** Extracts TB (PPD or IGRA), hepatitis B/C, and immunization status from FHIR data for comprehensive submission.
• **Periodic Re-authorization:** Manages typical 6/12-month cycles with automated prompts for continuous disease-activity and response documentation.
• **Benefit Routing:** Intelligently routes agents based on administration mode, ensuring correct medical-vs-pharmacy benefit submission.

Strategic Advantages for Illinois Healthcare Providers

Implementing Klivira for biologics prior auth in Illinois translates to tangible benefits for revenue cycle management and patient care. By reducing administrative overhead and improving PA turnaround times, health systems can mitigate claim denials, optimize staff utilization, and enhance patient satisfaction. Our platform provides the operational efficiency needed to navigate the complexities of specialty drug access within Illinois' diverse healthcare ecosystem.